Key result
Peripheral blood visfatin concentrations were significantly higher in patients with coronary artery disease compared to controls (WMD 4.72 ng/mL; 95% CI 2.97-6.47; P < .001).
Why the study?
Are peripheral blood visfatin concentrations higher in patients with coronary artery disease compared to controls?
Meta-Analysis (n=1,767)
Are peripheral blood visfatin concentrations higher in patients with coronary artery disease compared to controls?
Increased peripheral blood visfatin concentrations are significantly associated with coronary artery disease and may serve as a risk marker.
May flag elevated CAD risk; leaves open incremental prognostic value beyond traditional markers.
A comprehensive quantitative evaluation of the relationship between peripheral blood visfatin concentrations and coronary artery disease (CAD) is lacking. This study is the first attempt to quantify this relationship via a meta-analysis of published observational studies in terms of weighted mean difference (WMD). Literature retrieval, article selection, and data extraction were conducted. Heterogeneity was inspected using both subgroup and meta-regression analyses. In total, 15 articles involving 1053 CAD cases and 714 controls were included. Overall, peripheral blood visfatin concentrations were significantly higher in CAD cases than in controls (WMD: 4.72 ng/mL; 95% confidence interval [CI]: 2.97-6.47; P < .001), with significant heterogeneity and publication bias. Six studies were theoretically missing based on filled funnel plot, and considering the impact of these missing studies still detected a significant overall mean difference in visfatin (WMD: 2.82 ng/mL; 95% CI: 2.22-3.58; P < .001; number of studies: 21). Subgroup and meta-regression analyses indicated age, body mass index, race, diabetes, systolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were identified as possible causes of heterogeneity. In conclusion, our findings suggest that increased peripheral blood visfatin concentrations may be a risk marker of CAD.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2018) conducted a meta-analysis in Coronary artery disease (n=1,767). Increased peripheral blood visfatin concentrations vs. Controls was evaluated on Difference in peripheral blood visfatin concentrations between CAD cases and controls (WMD 4.72, 95% CI 2.97-6.47, p=< .001). Peripheral blood visfatin concentrations were significantly higher in patients with coronary artery disease compared to controls (WMD 4.72 ng/mL; 95% CI 2.97-6.47; P < .001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: